These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 20237102)

  • 1. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.
    Juréen P; Angeby K; Sturegård E; Chryssanthou E; Giske CG; Werngren J; Nordvall M; Johansson A; Kahlmeter G; Hoffner S; Schön T
    J Clin Microbiol; 2010 May; 48(5):1853-8. PubMed ID: 20237102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.
    Angeby KA; Jureen P; Giske CG; Chryssanthou E; Sturegård E; Nordvall M; Johansson AG; Werngren J; Kahlmeter G; Hoffner SE; Schön T
    J Antimicrob Chemother; 2010 May; 65(5):946-52. PubMed ID: 20332195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
    Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
    J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.
    Sturegård E; Ängeby KA; Werngren J; Juréen P; Kronvall G; Giske CG; Kahlmeter G; Schön T
    Clin Microbiol Infect; 2015 Feb; 21(2):148.e5-7. PubMed ID: 25640156
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Dijkstra JA; van der Laan T; Akkerman OW; Bolhuis MS; de Lange WCM; Kosterink JGW; van der Werf TS; Alffenaar JWC; van Soolingen D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reevaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing.
    Werngren J; Sturegård E; Juréen P; Ängeby K; Hoffner S; Schön T
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1253-7. PubMed ID: 22203587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System.
    Rodrigues C; Jani J; Shenai S; Thakkar P; Siddiqi S; Mehta A
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1449-55. PubMed ID: 19017456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
    Sirgel FA; Tait M; Warren RM; Streicher EM; Böttger EC; van Helden PD; Gey van Pittius NC; Coetzee G; Hoosain EY; Chabula-Nxiweni M; Hayes C; Victor TC; Trollip A
    Microb Drug Resist; 2012 Apr; 18(2):193-7. PubMed ID: 21732736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.
    Maus CE; Plikaytis BB; Shinnick TM
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
    Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis.
    Engström A; Perskvist N; Werngren J; Hoffner SE; Juréen P
    J Antimicrob Chemother; 2011 Jun; 66(6):1247-54. PubMed ID: 21427106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.
    Rüsch-Gerdes S; Pfyffer GE; Casal M; Chadwick M; Siddiqi S
    J Clin Microbiol; 2006 Mar; 44(3):688-92. PubMed ID: 16517840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis.
    Via LE; Cho SN; Hwang S; Bang H; Park SK; Kang HS; Jeon D; Min SY; Oh T; Kim Y; Kim YM; Rajan V; Wong SY; Shamputa IC; Carroll M; Goldfeder L; Lee SA; Holland SM; Eum S; Lee H; Barry CE
    J Clin Microbiol; 2010 Feb; 48(2):402-11. PubMed ID: 20032248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium tuberculosis rrs A1401G mutation correlates with high-level resistance to kanamycin, amikacin, and capreomycin in clinical isolates from mainland China.
    Du Q; Dai G; Long Q; Yu X; Dong L; Huang H; Xie J
    Diagn Microbiol Infect Dis; 2013 Oct; 77(2):138-42. PubMed ID: 23948547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of the in vitro antimycobacterial activities of six aminoglycoside antibiotics using an agar dilution method.
    Udou T
    J Chemother; 2006 Dec; 18(6):610-6. PubMed ID: 17267338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.
    Torrea G; Coeck N; Desmaretz C; Van De Parre T; Van Poucke T; Lounis N; de Jong BC; Rigouts L
    J Antimicrob Chemother; 2015 Aug; 70(8):2300-5. PubMed ID: 25977401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China.
    Zhang X; Zhao B; Huang H; Zhu Y; Peng J; Dai G; Jiang G; Liu L; Zhao Y; Jin Q
    J Antimicrob Chemother; 2013 Jul; 68(7):1537-42. PubMed ID: 23539239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.
    Brossier F; Pham A; Bernard C; Aubry A; Jarlier V; Veziris N; Sougakoff W;
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the BACTEC MGIT 960 system for drug susceptibility testing of Mycobacterium tuberculosis isolates compared with the proportion method on solid media].
    Abe C; Aono A; Hirano K
    Kekkaku; 2001 Oct; 76(10):657-62. PubMed ID: 11712386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.